Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.

Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy.

from NYT > Health https://ift.tt/31qCvEy
via health&fitness